Publicaties
Gekozen filters:
Gekozen filters:
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines Universiteit Antwerpen
The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR-targeted therapies such as cetuximab, therapeutic resistance has become a major clinical problem, and new treatment options are therefore necessary. Moreover, the relationship between HER receptors, anti-EGFR therapies, and the human papillomavirus (HPV) status in HNSCC is not fully ...
Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study Universiteit Hasselt
Background: The Belgian Precision initiative aims to implement tumor-agnostic NGS in advanced cancer patients (pts) and enhance access to genotype-matching drugs. The current study aimed to investigate the efficacy of afatinib in advanced pre-treated solid cancers with an EGFR (excluding non-small cell lung cancer (NSCLC)), HER2 or HER3 mutation.
Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer Vrije Universiteit Brussel KU Leuven Universiteit Gent
AIMS: A few reports have assessed HER2 status in breast cancer by both dual-probe fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in an unselected and consecutive fashion, but CEP17 and HER2 copy number were not evaluated separately in these studies. Therefore, the aim of this study was to perform FISH testing for HER2 in a large number of breast tumours, irrespective of the IHC scores, which were also determined in ...
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer KU Leuven
BACKGROUND: In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher ...
Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer Universiteit Hasselt
HER2-positive breast cancer is one of the most prevalent forms of cancer among women worldwide. Generally, the molecular characteristics of this breast cancer include activation of human epidermal growth factor receptor-2 (HER2) and hormone receptor activation. HER2-positive is associated with a higher death rate, which led to the development of a monoclonal antibody called trastuzumab, specifically targeting HER2. The success rate of ...
Cascaded Bragg gratings in photonic crystal fiber for plasmonic cladding mode-based biosensing of HER2 protein Vrije Universiteit Brussel
Spectral multiplexing of biosensors in a single optical fiber has been a long-standing challenge, which we address here for the first time by combining photonic crystal fibers (PCF) with fiber Bragg grating technology. We exploit the features of the optical transmission spectrum of a straight fiber Bragg grating written in a PCF that allows exciting cladding mode resonances within a spectral span of about 60 nm, which is significantly narrower ...
Synthesis, preclinical validation, dosimetry and toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer Vrije Universiteit Brussel
Nanobodies are the smallest fully functional antigen-binding antibody fragments possessing ideal properties as probes for molecular imaging. In this study we labeled the anti-human epidermal growth factor receptor type 2 (HER2) Nanobody with (68)Ga via a 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) derivative and assessed its use for HER2 iPET imaging.
METHODS:
The 2Rs15dHis6 Nanobody and the lead optimized ...
METHODS:
The 2Rs15dHis6 Nanobody and the lead optimized ...